The MS Market is currently about $20 billion and rising, Having realised that people with MS would pay a lot for drugs that were not very effective, with increasingly active drugs the cost soars ever higher. In the USA it means increasing insurance costs and in the UK it means NICE first delay access to drugs as they haggle down the cost and probably NHS rationing will start as trusts seek to limit prescribing of drugs that will ultimately bankrupt them. The Risk Sharing Scheme results have allowed companies to hike their price.
The solution will have to wait until patents expire and chemicals arrive, but companies will do their utmost to ensure that they don't do that in a hurry.
Alternatively we could develop a generic (or could we?) if there was a will and a pathway to do it. Surprisingly there seems to be neither.
What happens when we have neuroprotective and remyelinating drugs what will the costs be then? Who will get there first academia or pharma...I know where my money is placed.